lifestyle.californiaconsumerbanking.com

Author: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

May 3, 2026
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing

May 1, 2026
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

April 30, 2026
Calidi Biotherapeutics Announces Proposed Public Offering

April 30, 2026
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

March 11, 2026
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

March 10, 2026
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

January 28, 2026